Efficacy and safety of a low-dose nivolumab regimen (240 mg) as neoadjuvant immunochemotherapy in Chinese patients with resectable non-small cell lung cancer: a prospective single-arm, exploratory study

International Immunopharmacology 2026

View at publisher

Authors: Zhengdong Cheng, Yating Ai, Yan Lin, Ying Wu, Shaoyun Nie, Zhuchen Yu, Juntao Zou

DOI: 10.1016/j.intimp.2026.116481

Cited by: 0

References: 39

Fields of Study & Subjects

Lung Cancer Diagnosis and Treatment Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations

References 39